Race Does Not Predict Prostate Cancer Metastasis Development

Race Does Not Predict Prostate Cancer Metastasis Development
Race Does Not Predict Prostate Cancer Metastasis Development

Race is not associated with the development of metastases in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a study published in the journal Cancer.1

Despite race being associated with disease progression in patients with early stage prostate cancer, how race contributes to outcomes in men who already have advanced disease is unclear.

Therefore, researchers sought to assess whether black men with CRPC and no known metastases would have a higher risk of metastatic disease in an equal-access setting.

For the study, investigators analyzed data from 837 men with M0/Mx CRPC diagnosed between 2000 and 2014 and received care at 5 Veteran Affairs hospitals.

Results showed that the 306 black men were equally as likely as the 531 nonblack men to receive a first and second bone scan following diagnosis of CRPC.

The study demonstrated no significant differences in the risk of metastasis development, bone metastases, time to bone scans, or overall survival between black patients and nonblack patients (all P >.2).

The findings ultimately suggest that studies seeking to understand prostate cancer racial disparities may derive greater benefit by evaluating the impact of race on the risk of developing prostate cancer and on the outcomes of patients with early stage disease.

Reference

1. Whitney CA, Howard LE, Amling CL, et al. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. Cancer. 2016 Aug 9. doi: 10.1002/cncr.30221. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs